Karyopharm Therapeutics
Tracked across 3 events · 47 articles · First seen May 25, 2026 · Last active Aug 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Karyopharm is the subject of the investigation; its stock dropped 21.45% following the disclosure of retention awards, and it faces potential securities fraud claims.
Jul 30, 2026 · 6 articles
Tech
Impact: Karyopharm Therapeutics, a partner of AnBogen Therapeutics, Inc., presented late-breaking oral presentation data from the SENTRY trial of selinexor in myelofibrosis, which could enhance its product's market adoption.
May 25, 2026 · 33 articles
Tech
Impact: Karyopharm Therapeutics conducted the SENTRY trial in collaboration with Menarini Group and markets selinexor in the U.S., benefiting from the positive trial data.
Jun 14, 2026 · 8 articles
ERGEN INTELLIGENCE
Track Karyopharm Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard